The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France
Journal of Cystic Fibrosis · 2026-07 · 25 (4) · 664-669
DOI: 10.1016/j.jcf.2026.03.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026-07. Verfasst von Théo Dhôte und 17 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, Institut Cochin, INSERM U1016, CNRS-UMR-8104, Paris, France; Department of Respiratory Medicine, National Reference Cystic Fib…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Lung Transplantation, Benzodioxoles, Indoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association Vaincre la Mucoviscidose.
Abstract (Originalsprache)
BACKGROUND: Several countries reported a reduction in lung transplants for people with cystic fibrosis (pwCF) after elexacaftor-tezacaftor-ivacaftor (ETI) was introduced. We sought to evaluate how lung transplant indications evolved in relation to CFTR genotypes and the use of ETI. METHODS: All lung transplants performed on pwCF in France between 2015 and 2024 were identified using data from the French Agence de la Biomédecine. Individual-level patient data, including CFTR genotypes and use of ETI at the time of transplant, were obtained from the French CF reference network centers. RESULTS: Between 2015 and 2024, a total of 538 lung transplants were performed, including 461 first-time transplants and 77 re-transplants. The rate of first-time lung transplant was 13.4 per 1000 non-transplanted patients/year versus 1.8 per 1000 non-transplanted patients/year for 2015-2019 (prior to ETI availability) and 2020-2024 (following ETI availability), respectively (P < 0.0001); the rate of lung re-transplant was 10.2 per 1000 transplanted patients/year versus 7.7 per 1000 transplanted patients/year (P = 0.70). Treatment with ETI was prescribed prior to transplant in all F508del pwCF who received a first-time transplant since 2021 and in all those with non-F508del ETI-responsive variants since 2022. Eleven patients treated with ETI required lung transplant due to adverse effects leading to ETI discontinuation, concomitant severe liver disease or insufficient improvement of respiratory failure. CONCLUSION: ETI has reduced, but not eliminated, the need for a first-time lung transplant in pwCF. Indications for a first-time lung transplant persist in a small subset of pwCF who respond to ETI and in those with nonresponsive CFTR genotypes. Re-transplant remains an option for selected transplant recipients with chronic lung allograft dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, Institut Cochin, INSERM U1016, CNRS-UMR-8104, Paris, France; Department of Respiratory Medicine, National Reference Cystic Fibrosis Center, Cochin Hospital, Assistance Publique Hôpitaux de Paris,…
- Pneumology, Adult Cystic Fibrosis Center and Lung Transplant Department Hôpital Foch, Suresnes, France.
- Department of Respiratory Medicine and Lung Transplant, APHM, Hôpital Nord, Aix Marseille Univ, Marseille, France.
- Hospices civils de Lyon, Hôpital Louis Pradel, Service de Pneumologie, Bron, France.
- Department of Respiratory Medicine and Lung Transplant, CHU de Strasbourg, Strasbourg, France.
- INSERM, Service de Pneumologie, Center for Research in Transplant and Translational Immunology, UMR 1064, l'institut du thorax, Nantes Université, CHU Nantes, Nantes, France.
Förderung
- Association Vaincre la Mucoviscidose
Zitieren
APA
Dhôte, T., Grenet, D., Reynaud-Gaubert, M., Chatron, E., Renaud-Picard, B., Tissot, A., Macey, J., Murris-Espin, M., Bunel, V., Sermet-Gaudelus, I., Carlier, N., Boussaud, V., Kanaan, R., Legeai, C., Dorent, R., de Miranda, S., Da Silva, J., & Burgel, P. R. (2026). The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France. Journal of Cystic Fibrosis, 25(4), 664-669. https://doi.org/10.1016/j.jcf.2026.03.003
Vancouver
Dhôte T, Grenet D, Reynaud-Gaubert M, Chatron E, Renaud-Picard B, Tissot A, et al. The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France. Journal of Cystic Fibrosis. 2026;25(4):664-669. doi:10.1016/j.jcf.2026.03.003
BibTeX
@article{Dhte2026,
author = {Dhôte, Théo and Grenet, Dominique and Reynaud-Gaubert, Martine and Chatron, Eva and Renaud-Picard, Benjamin and Tissot, Adrien and Macey, Julie and Murris-Espin, Marlène and Bunel, Vincent and Sermet-Gaudelus, Isabelle and Carlier, Nicolas and Boussaud, Véronique and Kanaan, Reem and Legeai, Camille and Dorent, Richard and de Miranda, Sandra and Da Silva, Jennifer and Burgel, Pierre-Régis},
title = {The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France},
journal = {Journal of Cystic Fibrosis},
year = {2026},
volume = {25},
number = {4},
pages = {664--669},
doi = {10.1016/j.jcf.2026.03.003}
}
EUVIMED